# A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

> **NCT06917690** · PHASE3 · RECRUITING · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 6 (estimated)

## Conditions studied

- Epidermolysis Bullosa
- Junctional Epidermolysis Bullosa
- Epidermolysis Bullosa, Dystrophic
- Epidermolysis Bullosa, Junctional
- Skin Abnormalities
- Connective Tissue Disease
- Collagen Diseases
- Skin Diseases
- Genetic Diseases, Inborn
- Congenital Abnormalities

## Interventions

- **DRUG:** Oleogel-S10

## Key facts

- **NCT ID:** NCT06917690
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-18
- **Primary completion:** 2026-03
- **Final completion:** 2029-09
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917690, "A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06917690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*